Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Performance of a redesigned HIV selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants
Clinical and Vaccine Immunology, Volume 21, No. 3, Year 2014
Notification
URL copied to clipboard!
Description
Vaccine-induced seropositivity (VISP) or seroreactivity (VISR), defined as the reaction of antibodies elicited by HIV vaccines with antigens used in HIV diagnostic immunoassays, can result in reactive assay results for vaccinated but uninfected individuals, with subsequent misclassification of their infection status. The eventual licensure of a vaccine will magnify this issue and calls for the development of mitigating solutions in advance. An immunoassay that discriminates between antibodies elicited by vaccine antigens and those elicited by infection has been developed to address this laboratory testing need. The HIV Selectest is based on consensus and clade-specific HIV peptides that are omitted in many HIV vaccine constructs. The assay was redesigned to enhance performance across worldwide clades and to simplify routine use via a standard kit format. The redesigned assay was evaluated with sera from vaccine trial participants, HIV-infected and uninfected individuals, and healthy controls. The HIV Selectest exhibited specificities of 99.5% with sera from uninfected recipients of 6 different HIV vaccines and 100% with sera from normal donors, while detecting HIV-1 infections, including intercurrent infections, with 95 to 100% sensitivity depending on the clade, with the highest sensitivities for clades A and C. HIV Selectest sensitivity decreased in very early seroconversion specimens, which possibly explains the slightly lower sensitivity observed for asymptomatic blood donors than for clinical HIV cases. Thus, the HIV Selectest provides a new laboratory tool for use in vaccine settings to distinguish the immune response to HIV vaccine antigens from that due to true infection. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Penezina, Oksana P.
United States, Cambridge
Immunetics, Inc.
Krueger, Neil X.
United States, Cambridge
Immunetics, Inc.
Rodriguez-Chavez, Isaac R.
United States, Bethesda
National Institute of Dental and Craniofacial Research Nidcr
Busch, Michael P.
United States, San Francisco
Vitalant Research Institute
Hural, John A.
United States, Seattle
Fred Hutchinson Cancer Research Center
Kim, Jerome Hahn
United States, Silver Spring
Walter Reed Army Institute of Research
O'Connell, Robert J.
United States, Silver Spring
Walter Reed Army Institute of Research
Thailand, Bangkok
Armed Forces Research Institute of Medical Sciences, Thailand
Hunter, Eric
United States, Atlanta
Emory University
Aboud, Said
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Higgins, Keith W.
United States, San Francisco
Global Solutions for Infectious Diseases
Kovalenko, Victor A.
United States, Cambridge
Immunetics, Inc.
Clapham, David
United States, Cambridge
Immunetics, Inc.
Crane, David
United States, Cambridge
Immunetics, Inc.
Levin, Andrew E.
United States, Cambridge
Immunetics, Inc.
Rerks-Ngarm, Supachai
Thailand, Nontaburi
Thailand Ministry of Public Health
Pitisuttithum, Punnee
Thailand, Nakhon Pathom
Mahidol University
Nitayaphan, Sorachai
Thailand, Bangkok
Armed Forces Research Institute of Medical Sciences, Thailand
Kaewkungwal, J.
Thailand, Nakhon Pathom
Mahidol University
Andrews, Charla A.
United States, Silver Spring
Walter Reed Army Institute of Research
Kilembe, William
United States, Atlanta
Emory University
Karita, Etienne
United States, Atlanta
Emory University
Allen, Susan A.
United States, Atlanta
Emory University
Munseri, Patricia Jane
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Joachim, Agricola
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Bakari, Muhammad
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Mhalu, Frederick S.
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Aris, Eric A.
Tanzania, Dar es Salaam
Muhimbili National Hospital
Nilsson, Charlotta
Sweden, Stockholm
Karolinska Institutet
Sweden, Solna
Public Health Agency of Sweden
Biberfeld, Gunnel
Sweden, Stockholm
Karolinska Institutet
Sweden, Solna
Public Health Agency of Sweden
Robb, Merlin Lee
United States, Rockville
Hjf
Marovich, Mary Anne
United States, Silver Spring
Walter Reed Army Institute of Research
Sandström, Eric G.
Sweden, Stockholm
Karolinska Institutet
Statistics
Citations: 32
Authors: 32
Affiliations: 15
Identifiers
Doi:
10.1128/CVI.00748-13
ISSN:
15566811
e-ISSN:
1556679X
Research Areas
Infectious Diseases